Navigation Links
ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

p>

R&D expenses increased by $3.9 million, or 33%, to $15.9 million for 2007, from $12.0 million for 2006. The increase in 2007 was primarily due to a $2.3 million increase in expenses related to external preclinical, research-related manufacturing, quality assurance and regulatory activities, a $1.5 million increase in personnel-related costs and a $223,000 increase in external clinical expenses. R&D expenses for 2007 included non-cash, share-based compensation expense amounting to $1.1 million, compared to $510,000 for 2006.

SG&A expenses increased by $1.4 million, or 20%, to $8.7 million for 2007, from $7.2 million for 2006. The increase in 2007 was substantially due to a $1.0 million increase in personnel and related costs and a $321,000 increase in legal fees, of which $204,000 was related to the enforcement of our rights under the Theragenex license agreement, which we terminated in August 2007. SG&A expenses for 2007 included non-cash, share-based compensation expenses amounting to $1.4 million, compared to $1.6 million for 2006.

Revenue of $500,000 in 2007 represented a license fee earned from licensing ANX-211, compared to no revenue earned in 2006. Interest income amounted to $2.2 million in 2007, compared to $1.2 million in 2006. The increase in interest income in 2007 was due to a higher average invested balance primarily as a result of an equity financing in November 2006 and a higher average interest rate in 2007.

During 2007, the Company made significant additions and changes to the management team, including the appointment of a vice president of commercialization and a vice president of regulatory affairs.

Balance Sheet Highlights

As of December 31, 2007, the Company had cash, cash equivalents and investments in securities totaling $33.5 million, with cash and cash equivalents of $14.8 million and short-term investments in securities of $18.7 million. Stockholders' equity amounted to $31.0 million as of December
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
4. ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
5. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
6. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
9. ADVENTRX Appoints Vice President of Commercialization
10. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
11. ADVENTRX Announces Consolidation of Clinical and Management Positions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 More than 5 million Americans ... in 3 seniors will die with Alzheimer’s or another ... figures have shocked many Americans into looking for ways ... these tragic age-related cognitive disorders. Jonathan Weisman, president of ...
(Date:1/15/2014)... 2014 2013 was a banner year ... Technologies®. They saw continued independent research led by the ... awarded a $1 million grant from the Susanne Marcus ... Behavior” a peer reviewed journal, Amy Grant highlighted Brainwave ...
(Date:1/14/2014)... 14, 2014 Date: Friday, April 11, 2014 ... Country Club, 1360 Almshouse Road, Warrington, Pa. , ... solely dedicated to finding a cure for hepatitis B and ... host its annual Crystal Ball on Friday, April 11 at ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s resolutions ... care of my furry companion." Nowadays there are pet salons, dog ... to take the little canine or feline darlings along wherever mommy ... some pricey toys at the pet store. But anyone who has ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... - Tamiflu Remains Fully Effective ... Latest surveillance data coming through ... virologists and clinicians indicates that,the influenza A(H3N2) virus is ... on the data published by ECDC Roche confirms that ...
... Conn., Jan. 19 SurgiQuest, Inc. is pleased to ... agreement with Intuitive Surgical, Inc. (Nasdaq: ISRG ... system using AirSeal(TM) technology for use with Intuitive,s laparoscopic ... invasive surgical procedures because it allows the surgeon to ...
... Corporation,s (Amex: ETC ) ("ETC" or ... of two BARA-MED(R) XD Monoplace Hyperbaric Chambers for ... St. Luke,s Hospital - Allentown Campus is part ... a nationally recognized, regional, integrated network of non-profit ...
Cached Biology Technology:Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain 2Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain 3Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain 4SurgiQuest Signs a Development and Supply Agreement with Intuitive Surgical for MIS Access Utilizing the AirSeal(TM) Technology 2Environmental Tectonics Corporation Announces the Sale of Two BARA-MED(R) XD Monoplace Hyperbaric Chambers 2Environmental Tectonics Corporation Announces the Sale of Two BARA-MED(R) XD Monoplace Hyperbaric Chambers 3Environmental Tectonics Corporation Announces the Sale of Two BARA-MED(R) XD Monoplace Hyperbaric Chambers 4
(Date:7/9/2014)... with traumatic injuries have identified an immune marker ... a hospital-acquired infection. The study, led by clinician-scientists ... June in the journal Shock , is ... to the clinical implementation of quick-turnaround immune function ... system damage following critical illness or injury in ...
(Date:7/9/2014)... shark species may be able to cope with the rising ... , The Arctic today is best known for its tundra ... Roughly 53 to 38 million years ago during what is ... to a huge temperate forest with brackish water, home to ... creatures, crocodiles and giant tortoises. Much of what is known ...
(Date:7/9/2014)... U.S. may be on the verge of an economy driven ... cleaner than coal and is undergoing a production boom. It ... but recent research is casting serious doubts over just how ... & Engineering News (C&EN), the weekly news magazine of ... a senior correspondent at C&EN, explains that when burned as ...
Breaking Biology News(10 mins):Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... SLOVENIARidge and furrow rainwater-harvesting (RFRH) systems with mulches were ... northwest China to improve water availability and to increase ... rainwater harvesting zones, and bare or mulched furrows serve ... and are being promoted in many parts of the ...
... that can cope with sudden fluctuations in the weather could ... of plants. Scientists studying how tiny algae renew ... useful in developing crops suited to climates in which weather ... protein renewal takes place dictates how quickly they can adapt ...
... A manmade package filled with nature,s bone-building ingredients delivers ... bone injuries faster than products currently available, Cleveland researchers ... surgical elastic "implant device," essentially a wrapping that mimics ... growth factors and other natural components of the periosteum ...
Cached Biology News:Improved rainwater harvesting system promising 2It's all in the wrapping 2
Goat polyclonal to Rabenosyn 5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: ELKHTLAKQKGGTD, corresponding to C terminal amino acids 771-784 of Human Rabenosyn 5. Entr...
Acetyl CoA Carboxylase Antibody...
Anti-Human IFN-Gamma Receptor Chain 2 (beta chain) [CD119], Rabbit serum, NON-neutralizing polyclonal antibody...
AANAT [Arylalkylamine N-acetyltransferase; EC 2.3.1.87]...
Biology Products: